Company

ArkBio Publishes Pivotal Phase 3 Data for Azstarys in Chinese Children with ADHD – NMPA‑Approved Dual‑Release Formulation Nears Commercial Launch
Ark BiopharmaceuticalClinical trial results

ArkBio Publishes Pivotal Phase 3 Data for Azstarys in Chinese Children with ADHD – NMPA‑Approved Dual‑Release Formulation Nears Commercial Launch

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that results from the pivotal Phase 3 trial of Azstarys™ (serdexmethylphenidate chloride and dexmethylphenidate hydrochloride capsules) in Chinese children aged 6–12 years with…

GenFleet's Oral KRAS G12D Inhibitor GFH375/VS‑7375 Delivers Positive Data Across Global Studies – World's First KRAS G12D Agent in Phase III for NSCLC and Pancreatic Cancer

GenFleet’s Oral KRAS G12D Inhibitor GFH375/VS‑7375 Delivers Positive Data Across Global Studies – World’s First KRAS G12D Agent in Phase III for NSCLC and Pancreatic Cancer

Centergate Technologies Subsidiary Duoduo Pharmaceutical Has Calcium Dobesilate Capsules Application Accepted by NMPA – Generic Filing Enters Review for Established Capillary Protectant

Centergate Technologies Subsidiary Duoduo Pharmaceutical Has Calcium Dobesilate Capsules Application Accepted by NMPA – Generic Filing Enters Review for Established Capillary Protectant

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength
Finanical ReportsNASDAQ: REGN

Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength

Gilead SciencesHIV / AIDS care

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Hansoh PharmaceuticalHengrui Pharmaceuticals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Basecare MedicalHKG: 2170

Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit

Show More